Inclusion Criteria:

In order to be eligible to participate in this study, an individual must meet all of the
following criteria:

1. ≥ 18 years of age at the time of enrollment

2. PROMIS-Cog T-score < 40

3. Previous suspected, probable, or confirmed SARS-CoV-2 infection, as defined by the
Pan American Health Organization

Suspected case of SARS-CoV-2 infection - three options, A through C:

A. Met clinical OR epidemiological criteria:

a. Clinical criteria: Acute onset of fever AND cough (influenza-like illness) OR
Acute onset of ANY THREE OR MORE of the following signs or symptoms: fever, cough,
general, weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea, nausea,
diarrhea, anorexia; b. Epidemiological criteria: Contact of a probable or confirmed
case or linked to a COVID-19 cluster;

B. Presented acute respiratory infection with history of fever or measured fever of
≥ 38°C and cough, with onset within the last 10 days, and who requires
hospitalization; or

C. Presented with no clinical signs or symptoms, NOR meeting epidemiologic criteria
with a positive professional use or self-test SARS-CoV-2 Antigen-Rapid Diagnostic
Test.

Probable case of SARS-CoV-2 infection, defined as having met clinical criteria above
AND was a contact of a probable or confirmed case or was linked to a COVID-19
cluster.

Confirmed case of SARS-CoV-2 infection - two options, A through B:

A. Presented with a positive nucleic acid amplification test, regardless of clinical
criteria OR epidemiological criteria; or

B. Met clinical AND/OR epidemiological criteria (See suspected case A.a.), with a
positive professional use or self-test SARS-CoV-2 Antigen-Rapid Diagnostic Test.

* Suspected and probable cases will only be allowed if they occurred before May 1,
2021, and will be limited to 10% of the study population. Otherwise, confirmed cases
are required.

4. Cognitive dysfunction symptoms following a SARS-CoV-2 infection that have persisted
for at least 12 weeks and are still present at the time of consent

5. Fluent in English or Spanish language

6. Willing and able to provide informed consent, complete the intervention, complete
the intervention assessments, and return for all of the necessary follow-up visits

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation
in this study:

1. Prior or active unstable or progressive major psychiatric or neurologic condition
that would not show improvement and could hide treatment effect and is not related
to SARS-CoV-2 infection, at the investigator's discretion, including, but not
limited to, the following examples:

a. Progressive neurodegenerative disease, such as Alzheimer's disease, Parkinson's
disease, etc.

b. Past traumatic brain injury occurrence still associated with active
post-concussive symptoms c. Uncontrolled seizure disorder, such as having at least
one seizure in the last year that is adjudicated by clinical judgement d.
Post-stroke deficits that may interfere with assessment, such as language or
communication difficulties, aphasia, etc.

e. Formal thought disorders, such as schizophrenia, etc. f. Any neuropsychiatric or
neurologic disorder uncontrolled for the previous six months or that may interfere
with assessment, at discretion of the investigator

2. Known prior diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome, not
related to SARS-CoV-2 infection

3. Known active acute SARS-CoV-2 infection ≤ 4 weeks from consent

4. Current use of symptomatic therapies including prescribed or illicit stimulants,
amantadine, N-methyl-D-aspartate receptor antagonists (e.g., memantine, dissociative
drugs)

5. Current use of a stimulant for treating any PASC-related symptom

6. Current diagnosis of alcohol and substance use disorders

a. Prior use disorders acceptable if abstinence achieved and maintained for at least
12 months before study enrollment

7. Insufficient visual, auditory, and motor function to participate in intervention and
assessments

8. Known pregnancy

9. Current or recent use (within the last 2 months) of intervention*

10. Known allergy/sensitivity/hypersensitivity to components of the intervention or
comparator*

11. Currently receiving/using intervention from another clinical trial, such as another
RECOVER trial

12. Any condition that would make the participant, in the opinion of the investigator,
unsuitable for the study

1. The site investigator has the discretion to determine whether a participant is
too cognitively impaired to participate and should instead be referred for
clinical evaluation.

Exclusions specific to intervention appendices are listed in each appendix.

* Relevant if only one intervention appendix is open at the time of enrollment, though
exclusion may be qualified in the appendix. If multiple intervention appendices are open,
a participant may be excluded from any intervention appendix based on contraindications
listed in the intervention appendix, current use of intervention, or known
allergy/sensitivity/hypersensitivity and still remain eligible for the remaining
intervention appendices.